Fragment, Modified GRF, Ipamorelin Blend is a synthetic peptide mixture supplied exclusively for controlled laboratory research, analytical testing, and in vitro experimental use. The formulation contains Fragment 176-191, Modified GRF (1-29), and Ipamorelin.
The blend may be used in controlled research involving peptide characterization, receptor-interaction assays, GH-axis research models, and multi-compound analytical methods. Experimental use should include appropriate controls, validated procedures, and complete batch documentation.
Lot-specific analytical information is available through the Certificate of Analysis. Researchers should review the applicable COA for identity, purity, testing methods, and other batch-specific results.
The primary concern for peptide researchers today is product purity. Nord-sci guarantees our product purity by performing independent testing of our products and providing those certifications for our customers in our product descriptions.
THIS PRODUCT IS NOT INTENDED TO TREAT, CURE OR DIAGNOSE ANY CONDITION OR DISEASE AND IS NOT FOR HUMAN CONSUMPTION. ALL PRODUCTS OFFERED ARE INTENDED FOR LABORATORY RESEARCH USE ONLY.
All products are produced using lyophilization (freeze-drying), a preservation method that allows peptides to remain fully stable during shipping for approximately 3-4 months. Once a peptide has been reconstituted with bacteriostatic water, it must be refrigerated to maintain integrity. After reconstitution, peptides typically remain stable for up to 30 days when stored properly.
Lyophilization, also referred to as cryodesiccation, is a specialized dehydration process in which peptides are first frozen and then exposed to a low-pressure environment. This causes the water within the vial to transition directly from a solid to a vapor (sublimation), leaving behind a dry, crystalline white material known as a lyophilized peptide. In this powdered form, peptides may be safely stored at room temperature until they are ready to be reconstituted with bacteriostatic water.
After delivery, peptides should be protected from heat and light. If use is expected within the near future (whether days, weeks, or a few months) refrigerated storage below 4°C (39°F) is generally sufficient. Lyophilized peptides are commonly stable at room temperature for several weeks or longer, making short-term ambient storage acceptable when use is anticipated within that timeframe.
For extended storage, ranging from several months to multiple years, freezing is strongly recommended. Storage at -80°C (-112°F) offers optimal long-term stability and helps preserve peptide structure and quality over time.
For more detailed guidance on peptide handling and storage best practices, please refer to the resource below:
Fragment 176-191, Modified GRF (1-29), Ipamorelin Blend is a research-grade mixture intended for controlled laboratory investigation and analytical evaluation. It combines three synthetic peptide materials in a single lyophilized research format.
This blended material may be incorporated into experimental models involving peptide characterization, receptor-interaction methods, GH-axis assay systems, and the analytical behavior of multiple peptide constituents within the same sample. It may also be evaluated against individual-compound controls under standardized laboratory conditions.
Because blended materials contain multiple analytes, researchers should establish clearly defined endpoints, validated analytical methods, suitable controls, and consistent documentation procedures before beginning an experiment.
Fragment 176-191, Modified GRF (1-29), Ipamorelin Blend – Research Specifications:
| Product Name | Fragment 176-191, Modified GRF (1-29), Ipamorelin Blend |
| Contents | Fragment 176-191, Modified GRF (1-29), and Ipamorelin |
| Format | Lyophilized synthetic peptide blend |
| Appearance | Dry lyophilized material |
| Molecular Formula | No single molecular formula applies to the combined blend. Consult the constituent and lot-specific documentation. |
| Molecular Weight | No single molecular weight applies to the combined blend. Consult the constituent and lot-specific documentation. |
| CAS Number | No single CAS number applies to the combined blend. |
| Sequence Information | Refer to the identity documentation for each constituent peptide. |
| Purity and Identity | Consult the lot-specific Certificate of Analysis for reported analytical data. |
| Analytical Testing | Review the applicable COA for the testing methods used and reported batch results. |
| Storage Conditions | Store sealed in a cool, dry environment protected from heat, light, and moisture. Follow the product label and laboratory SOPs. |
| Intended Use | Laboratory research and analytical use only. |
| Restrictions | Not for human or animal consumption, clinical use, veterinary use, or diagnostic or therapeutic applications. |
Fragment 176-191 is a synthetic peptide corresponding to a defined C-terminal region of the human growth hormone sequence. Within laboratory research, it may be examined through peptide-characterization methods, binding assays, and pathway-specific experimental systems.
Modified GRF (1-29) is a synthetic analog based on the first 29 amino acids of growth hormone-releasing hormone. It may be incorporated into controlled research involving GHRH-receptor interaction, ligand characterization, and GH-axis assay development.
Ipamorelin is a synthetic peptide studied in laboratory systems involving the growth hormone secretagogue receptor. Research applications may include receptor-binding analysis, method validation, and comparative evaluation against other synthetic ligands.
Combining these materials allows laboratories to evaluate multiple peptide analytes under the same experimental conditions. Appropriate studies may compare the blend with its individual constituents, vehicle controls, reference standards, or other defined research materials.
Researchers requiring separate controls can review the individual product pages for Fragment 176-191, Modified GRF (1-29), and Ipamorelin.
Important Research Notice: Lot-specific Certificates of Analysis are available to assist with product verification, internal quality review, method alignment, and laboratory recordkeeping.
THIS PRODUCT IS INTENDED EXCLUSIVELY FOR LABORATORY RESEARCH. NOT FOR HUMAN OR ANIMAL CONSUMPTION. NOT INTENDED FOR DIAGNOSTIC, THERAPEUTIC, CLINICAL, VETERINARY, FOOD, COSMETIC, OR SUPPLEMENT USE.
The formulation may be evaluated using established laboratory methods for peptide identity, purity, and analytical characterization. Researchers should consult the lot-specific COA to determine which analytical methods and results apply to the supplied material.
Modified GRF (1-29) and Ipamorelin may be incorporated into controlled assay systems involving GHRH and growth hormone secretagogue receptor pathways. These studies should remain limited to qualified laboratory settings and clearly defined experimental endpoints.
The blend allows laboratories to examine three peptide constituents within a single research sample. Suitable applications may include chromatographic separation, mass-spectrometry method development, assay interference testing, stability analysis, and other multi-analyte procedures.
Researchers may compare the blended material with its individual constituents under standardized laboratory conditions. This structure can assist with evaluating analytical distinctions between a multi-component sample and corresponding single-compound controls without attributing the results to human or animal outcomes.
Handle the Fragment 176-191, Modified GRF (1-29), Ipamorelin Blend using established laboratory procedures for synthetic peptide materials. Appropriate practices include contamination control, calibrated equipment, documented sample identification, controlled environmental conditions, and complete experimental records.
Laboratory personnel should review the product label and lot-specific COA before incorporating the material into a research protocol. Experimental plans should account for the presence of multiple peptide constituents and include appropriate blanks, controls, standards, and validation procedures.
No information on this page provides instructions for dosing, administration, clinical application, veterinary application, or personal use.
This material may only be handled by qualified personnel in appropriately equipped research facilities.
Lot-specific analytical documentation is available for this peptide blend. The applicable Certificate of Analysis should be reviewed for reported identity, purity, testing methods, and other batch-specific information.
The COA can assist laboratories with procurement verification, incoming-material review, internal documentation, quality-control procedures, and research traceability. Analytical results should not be assumed to apply across different lots.
Nordsci Peptides supplies Fragment 176-191, Modified GRF (1-29), Ipamorelin Blend exclusively as a laboratory research material. Laboratories evaluating potential suppliers should review product identity, lot traceability, storage information, analytical documentation, and research-use restrictions before procurement.
IMPORTANT: This product is not a drug, food, dietary supplement, cosmetic, or medical product. It is not approved for human or animal use and must not be used for diagnostic, therapeutic, clinical, veterinary, or household applications. Purchasers are responsible for complying with applicable laws, institutional requirements, and laboratory safety procedures.
